WO2004063336A3 - Uses of deazapurines for the treatment of reperfusion injuries, osteoporosis and/or bone metastasis - Google Patents
Uses of deazapurines for the treatment of reperfusion injuries, osteoporosis and/or bone metastasis Download PDFInfo
- Publication number
- WO2004063336A3 WO2004063336A3 PCT/US2004/000293 US2004000293W WO2004063336A3 WO 2004063336 A3 WO2004063336 A3 WO 2004063336A3 US 2004000293 W US2004000293 W US 2004000293W WO 2004063336 A3 WO2004063336 A3 WO 2004063336A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- osteoporosis
- treatment
- deazapurines
- bone metastasis
- reperfusion injuries
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides methods of using compounds having formula (I) : wherein R1, R2, R3 and n are as described generally and in classes and subclasses herein, in the treatment of reperfusion injuries, osteoporosis and/or bone metastasis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2003/000366 WO2003057696A1 (en) | 2002-01-07 | 2003-01-07 | Deazapurines and uses thereof |
USPCT/US03/00366 | 2003-01-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004063336A2 WO2004063336A2 (en) | 2004-07-29 |
WO2004063336A3 true WO2004063336A3 (en) | 2004-08-26 |
Family
ID=32710267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/000293 WO2004063336A2 (en) | 2003-01-07 | 2004-01-07 | Uses of deazapurines for the treatment of reperfusion injuries, osteoporosis and/or bone metastasis |
Country Status (2)
Country | Link |
---|---|
TW (1) | TWI322807B (en) |
WO (1) | WO2004063336A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006210810B2 (en) | 2005-02-02 | 2012-03-08 | Eisai R & D Management Co., Ltd. | Crystalline 1H-imidazo[4,5-b]pyridin-5-amine,7-[5-[(cyclohexylmethylamino)-methyl]-1H-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0434405A1 (en) * | 1989-12-21 | 1991-06-26 | American Home Products Corporation | Imidazo[4,5-c]pyridines as antiosteoporotic agents |
WO2001030778A1 (en) * | 1999-10-27 | 2001-05-03 | Novartis Ag | Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use |
-
2003
- 2003-06-02 TW TW092114905A patent/TWI322807B/en not_active IP Right Cessation
-
2004
- 2004-01-07 WO PCT/US2004/000293 patent/WO2004063336A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0434405A1 (en) * | 1989-12-21 | 1991-06-26 | American Home Products Corporation | Imidazo[4,5-c]pyridines as antiosteoporotic agents |
WO2001030778A1 (en) * | 1999-10-27 | 2001-05-03 | Novartis Ag | Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use |
Non-Patent Citations (5)
Title |
---|
ABRAHAMSEN B ET AL: "CYTOKINES AND BONE LOSS IN A 5-YEAR LONGITUDINAL STUDY- HORMONE REPLACEMENT THERAPY SUPPRESSES SERUM SOLUBLE INTERLEUKIN-6 RECEPTOR AND INCREASES INTERLEUKIN-1-RECEPTOR ANTAGONIST: THE DANISH OSTEOPOROSIS PREVENTION STUDY", JOURNAL OF BONE AND MINERAL RESEARCH, NEW YORK, NY, US, vol. 15, no. 8, August 2000 (2000-08-01), pages 1545 - 1554, XP001012963, ISSN: 0884-0431 * |
CAIN B S ET AL: "p38 MAPK Inhibition Decreases TNF-alpha Production and Enhances Postischemic Human Myocardial Function", JOURNAL OF SURGICAL RESEARCH, ACADEMIC PRESS INC., SAN DIEGO, CA, US, vol. 83, no. 1, 1 May 1999 (1999-05-01), pages 7 - 12, XP002213908, ISSN: 0022-4804 * |
DANIELLE G. SOUZA ET AL.: "Effects of inhibition of PDE4 and TNF-a on local and remote injuries following ischaemia and reperfusion injury", BRITISH JOURNAL OF OHARMACOLOGY, vol. 134, no. 5, November 2001 (2001-11-01), LONDON, pages 985 - 994, XP002287701 * |
KOYANO T ET AL: "EFFECTS OF FR167653 ON ISCHEMIA-REPERFUSION INJURY: EVALUATION THROUGH PRESERVATION AND TRANSPLANTATION IN CANINE HEARTS", JOURNAL OF HEART AND LUNG TRANSPLANTATION, MOSBY-YEAR BOOK, INC., ST LOUIS, MO, US, vol. 17, no. 12, December 1998 (1998-12-01), pages 1247 - 1254, XP001105182, ISSN: 1053-2498 * |
YOSHIAKI AZUMA ET AL.: "Tumor Necrosis Factor-a Induces Differentiaion of and Bone Resorption by Osteoclasts", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 275, no. 7, 18 February 2000 (2000-02-18), USAMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD., pages 4858 - 4864, XP002287700 * |
Also Published As
Publication number | Publication date |
---|---|
TWI322807B (en) | 2010-04-01 |
TW200412345A (en) | 2004-07-16 |
WO2004063336A2 (en) | 2004-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL216579A0 (en) | Aminocyclohexyl ether derivatives and pharmaceutical compositions containing the same | |
WO2004074244A3 (en) | Pyrimidine compounds | |
RS20050810A (en) | 5,7-diaminopyrazolo(4,3-d)pyrimidines useful in the treatment of hypertension | |
TW200508214A (en) | Novel compounds | |
RS20060320A (en) | Substituted indazole-o-glucosides | |
SG130189A1 (en) | Substituted indole-o-glucosides | |
WO2007017289A3 (en) | Acyltryptophanols for fertility control | |
SG156650A1 (en) | Thienopyrimidines useful as aurora kinase inhibitors | |
PL369530A1 (en) | Chemical compounds | |
UA86042C2 (en) | Substituted indazole-o-glucosides | |
WO2007106192A3 (en) | Inhibitors of iap | |
TW200738659A (en) | Novel compounds | |
GB0307834D0 (en) | Composition | |
WO2007120333A3 (en) | Tetracyclic kinase inhibitors | |
TW200604197A (en) | New compounds | |
WO2005030794A3 (en) | Hemiasterlin derivatives and uses thereof | |
MXPA06003345A (en) | Aminopyridine-derivatives as inductible no-synthase inhibitors. | |
WO2004087652A3 (en) | Imidazotriazine compounds | |
WO2004063336A3 (en) | Uses of deazapurines for the treatment of reperfusion injuries, osteoporosis and/or bone metastasis | |
MXPA05012742A (en) | Hair treatment compositions. | |
WO2004050834A3 (en) | GPC99 AND GPC99a: METHODS AND COMPOSITIONS FOR TREATING CANCER | |
TW200503672A (en) | 2-aminobenzoyl derivatives | |
MX2007006094A (en) | 2-methylene-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol. | |
TW200714284A (en) | Novel method | |
UA80871C2 (en) | 5,7-diaminopyrazolo[4,3-d]pyrimidines useful in the treatment of hypertension |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |